Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?

Context: The term giant mandibular ameloblastoma (GMAs) while being in popular usage in the medical literature remains largely equivocal. Although a few authors have in the past attempted to ascribe definite criteria to this entity, these are by and large arbitrary and without any benefit in decisio...

Full description

Saved in:
Bibliographic Details
Main Authors: Aditya V. Kanoi, Tibar Banerjee, Narayanamurthy Sundaramurthy, Arindam Sarkar, Pooja Kanoi, Sushovan Saha
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2018-05-01
Series:Indian Journal of Plastic Surgery
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/ijps.IJPS_194_17
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849699483841986560
author Aditya V. Kanoi
Tibar Banerjee
Narayanamurthy Sundaramurthy
Arindam Sarkar
Pooja Kanoi
Sushovan Saha
author_facet Aditya V. Kanoi
Tibar Banerjee
Narayanamurthy Sundaramurthy
Arindam Sarkar
Pooja Kanoi
Sushovan Saha
author_sort Aditya V. Kanoi
collection DOAJ
description Context: The term giant mandibular ameloblastoma (GMAs) while being in popular usage in the medical literature remains largely equivocal. Although a few authors have in the past attempted to ascribe definite criteria to this entity, these are by and large arbitrary and without any benefit in decision-making or contributing to its management. Aims: The aim of this study is to propose a set of objective criteria for GMAs that can be clinically correlated and thereby aid in the management of this entity. Patients and Methods: Of a total of 16 patients with ameloblastoma of the mandible presenting at our institute from August 2012 to September 2016, 11 patients were identified as having GMAs as per the criteria proposed. Results: The defects in the mandible following segmental resection ranged from 7 to 11.5 cm in length (mean: 9.3 cm). No clinical or radiological evidence of tumour recurrence was found during a mean follow-up period of 10.7 months (range: 2–28 months). Conclusions: Defining GMA based on objective inclusion and exclusion criteria allows segregation of these lesions, thereby helping to remove ambiguity, simplify decision-making and facilitate communication among treating reconstructive surgeons. Inclusion criteria include: (i) The segmental bone defect following resection with a minimum 1 cm margin of healthy bone should exceed 6 cm (ii) The segmental bone defect should involve the central mandibular segment.
format Article
id doaj-art-2fb4ec2959384b61be6e1dfa3d1870e7
institution DOAJ
issn 0970-0358
1998-376X
language English
publishDate 2018-05-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Plastic Surgery
spelling doaj-art-2fb4ec2959384b61be6e1dfa3d1870e72025-08-20T03:18:34ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Plastic Surgery0970-03581998-376X2018-05-01510220821510.4103/ijps.IJPS_194_17Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?Aditya V. Kanoi0Tibar Banerjee1Narayanamurthy Sundaramurthy2Arindam Sarkar3Pooja Kanoi4Sushovan Saha5Department of Plastic and Reconstructive Surgery, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, IndiaDepartment of Plastic and Reconstructive Surgery, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, IndiaDepartment of Plastic and Reconstructive Surgery, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, IndiaDepartment of Plastic and Reconstructive Surgery, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, IndiaDepartment of Prosthodontics and Crown and Bridge, Manipal College of Dental Sciences, Mangaluru, Karnataka, IndiaDepartment of Plastic and Reconstructive Surgery, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, IndiaContext: The term giant mandibular ameloblastoma (GMAs) while being in popular usage in the medical literature remains largely equivocal. Although a few authors have in the past attempted to ascribe definite criteria to this entity, these are by and large arbitrary and without any benefit in decision-making or contributing to its management. Aims: The aim of this study is to propose a set of objective criteria for GMAs that can be clinically correlated and thereby aid in the management of this entity. Patients and Methods: Of a total of 16 patients with ameloblastoma of the mandible presenting at our institute from August 2012 to September 2016, 11 patients were identified as having GMAs as per the criteria proposed. Results: The defects in the mandible following segmental resection ranged from 7 to 11.5 cm in length (mean: 9.3 cm). No clinical or radiological evidence of tumour recurrence was found during a mean follow-up period of 10.7 months (range: 2–28 months). Conclusions: Defining GMA based on objective inclusion and exclusion criteria allows segregation of these lesions, thereby helping to remove ambiguity, simplify decision-making and facilitate communication among treating reconstructive surgeons. Inclusion criteria include: (i) The segmental bone defect following resection with a minimum 1 cm margin of healthy bone should exceed 6 cm (ii) The segmental bone defect should involve the central mandibular segment.http://www.thieme-connect.de/DOI/DOI?10.4103/ijps.IJPS_194_17ameloblastomafibula free flapjaw neoplasmsmandibular reconstructionnon-vascularised bone graftsegmental mandibulectomy
spellingShingle Aditya V. Kanoi
Tibar Banerjee
Narayanamurthy Sundaramurthy
Arindam Sarkar
Pooja Kanoi
Sushovan Saha
Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
Indian Journal of Plastic Surgery
ameloblastoma
fibula free flap
jaw neoplasms
mandibular reconstruction
non-vascularised bone graft
segmental mandibulectomy
title Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
title_full Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
title_fullStr Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
title_full_unstemmed Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
title_short Defining giant mandibular ameloblastomas – Is a separate clinical sub-entity warranted?
title_sort defining giant mandibular ameloblastomas is a separate clinical sub entity warranted
topic ameloblastoma
fibula free flap
jaw neoplasms
mandibular reconstruction
non-vascularised bone graft
segmental mandibulectomy
url http://www.thieme-connect.de/DOI/DOI?10.4103/ijps.IJPS_194_17
work_keys_str_mv AT adityavkanoi defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted
AT tibarbanerjee defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted
AT narayanamurthysundaramurthy defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted
AT arindamsarkar defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted
AT poojakanoi defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted
AT sushovansaha defininggiantmandibularameloblastomasisaseparateclinicalsubentitywarranted